Impact of rosuvastatin on pulse-wave velocity in men with HIV at moderate cardiovascular risk
Details
Publication Year 2024-09-01,Volume 38,Issue #11,Page 1722-1724
Journal Title
AIDS
Publication Type
Research article
Abstract
This single-centre substudy of a double-blind, randomized, placebo-controlled trial aimed to determine the effect of 96 weeks of rosuvastatin on pulse wave velocity (PWV) in men (n = 55, 54 years) with HIV at moderate cardiovascular risk (Framingham risk score 10-15%). PWV increased in both rosuvastatin [0.54 m/s standard error of difference (SED) 0.26] and placebo [0.50 m/s (SED 0.26), P = 0.896] arms, leading to no difference in PWV at week 96 [rosuvastatin 9.40 m/s (SE 0.31); placebo 9.21 m/s (SE0.31), P = 0.676].
Publisher
Wolters Kluwer
Keywords
Humans; *Rosuvastatin Calcium/therapeutic use/administration & dosage; Male; *HIV Infections/drug therapy/complications; Middle Aged; Double-Blind Method; *Pulse Wave Analysis; *Cardiovascular Diseases; Placebos/administration & dosage; Adult; Sulfonamides/therapeutic use/pharmacology; Treatment Outcome; Pyrimidines; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use; Fluorobenzenes/therapeutic use
Department(s)
Infectious Diseases
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-03 07:46:58
Last Modified: 2024-09-03 07:49:20

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙